Premium
Blastomycosis in solid organ transplant recipients—A retrospective series from southeastern Wisconsin
Author(s) -
Mehta Tej I.,
Kurman Jonathan,
Dolan Stephen,
Gill Harpreet,
Thapa Bipin
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13671
Subject(s) - blastomycosis , medicine , itraconazole , blastomyces , posaconazole , blastomyces dermatitidis , voriconazole , transplantation , surgery , organ transplantation , immunosuppression , fluconazole , dermatology , antifungal
Blastomycosis is a fungal infection caused primarily by Blastomyces dermatitis . The fungus is endemic to the Ohio, Mississippi, and St. Lawrence River areas of the United States. Organ transplant recipients are at risk of blastomycosis due to pharmacologic immunosuppression. Over a 20‐year period, 30 cases of blastomycosis post‐solid organ transplantation were identified at our center. The cumulative incidence of blastomycosis among SOT recipients was 0.99%. There was a male predominance (70% male) and a median age of 59 at the time of diagnosis. Regarding transplant type, 23 patients received kidney transplants, 4 received liver transplants, 2 received pancreas transplants and 1 received a heart transplant. Median time to blastomycosis identification post‐transplant was 67.8 months (range: 1‐188 months). Amphotericin B was used as initiation therapy in most cases, followed by itraconazole, voriconazole, or in select cases fluconazole or posaconazole maintenance therapy. Regarding comorbid conditions, 87% of patients had diabetes, 50% had congestive heart failure, and 20% had chronic pulmonary disease. Nine patients (30%) developed blastomycosis‐related acute respiratory distress syndrome, 33% of these died with a median time to death of 22 days (range 20 days to 2 months); these were the only deaths attributable to blastomycosis.